2. Academic Validation
  3. Epigenetic profiling identifies markers of endocrine resistance and therapeutic options for metastatic castration-resistant prostate cancer

Epigenetic profiling identifies markers of endocrine resistance and therapeutic options for metastatic castration-resistant prostate cancer

  • Cell Rep Med. 2025 Jul 15;6(7):102215. doi: 10.1016/j.xcrm.2025.102215.
Tesa M Severson 1,  Emma Minnee 2,  Yanyun Zhu 2,  Karianne Schuurman 3,  Holly M Nguyen 4,  Lisha G Brown 4,  Sini Hakkola 5,  Renee Menezes 6,  Sebastian Gregoricchio 2,  Yongsoo Kim 3,  Jeroen Kneppers 2,  Simon Linder 2,  Suzan Stelloo 2,  Cor Lieftink 7,  Michiel S van der Heijden 8,  Matti Nykter 5,  Vincent van der Noort 9,  Joyce Sanders 10,  Ben Morris 7,  Guido Jenster 11,  Geert Jlh van Leenders 12,  Mark Pomerantz 13,  Matthew L Freedman 14,  Roderick L Beijersbergen 7,  Alfonso Urbanucci 15,  Lodewyk Wessels 16,  Peter S Nelson 17,  Eva Corey 4,  Stefan Prekovic 2,  Wilbert Zwart 18,  Andries M Bergman 19
Affiliations

Affiliations

  • 1 Division of Oncogenomics, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands; Cancer Genomics Netherlands, Oncode Institute, 3584 CG Utrecht, the Netherlands; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands.
  • 2 Division of Oncogenomics, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands; Cancer Genomics Netherlands, Oncode Institute, 3584 CG Utrecht, the Netherlands.
  • 3 Division of Oncogenomics, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands.
  • 4 Department of Urology, University of Washington, Seattle, WA 98195, USA.
  • 5 Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Centre, 33100 Tampere, Finland.
  • 6 Biostatistics Centre & Department of Psychosocial Research and Epidemiology, the Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands.
  • 7 Division of Molecular Carcinogenesis and NKI Robotics and Screening Center, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands.
  • 8 Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands; Division of Medical Oncology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands.
  • 9 Department of Biometrics, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands.
  • 10 Department of Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands.
  • 11 Department of Urology, Erasmus MC, 3015 GD Rotterdam, the Netherlands.
  • 12 Department of Pathology, Erasmus MC Cancer Institute, 3015 CP Rotterdam, the Netherlands.
  • 13 Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
  • 14 Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; The Eli and Edythe L. Broad Institute, Cambridge, MA 02142, USA.
  • 15 Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Centre, 33100 Tampere, Finland; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, 0424 Oslo, Norway.
  • 16 Cancer Genomics Netherlands, Oncode Institute, 3584 CG Utrecht, the Netherlands; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands; Department of EEMCS, Delft University of Technology, 2628 CM Delft, the Netherlands.
  • 17 Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA 98195, USA.
  • 18 Division of Oncogenomics, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands; Cancer Genomics Netherlands, Oncode Institute, 3584 CG Utrecht, the Netherlands; Laboratory of Chemical Biology and Institute for Complex Molecular Systems, Department of Biomedical Engineering, Eindhoven University of Technology, 5600 MB Eindhoven, the Netherlands. Electronic address: w.zwart@nki.nl.
  • 19 Division of Oncogenomics, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands; Division of Medical Oncology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands; Department of Medical Oncology, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, the Netherlands. Electronic address: a.bergman@nki.nl.
PMID: 40609538 DOI: 10.1016/j.xcrm.2025.102215
Abstract

Androgen Receptor (AR) signaling inhibitors, including enzalutamide, are treatment options for patients with metastatic castration-resistant prostate Cancer (mCRPC), but resistance inevitably develops. Using metastatic samples from a prospective phase 2 clinical trial, we epigenetically profile enhancer/promoter activities with acetylation of lysine residue 27 on histone 3 (H3K27ac) chromatin immunoprecipitation followed by Sequencing, before and after AR-targeted therapy. We identify a distinct subset of H3K27ac-differentially marked regions that are associated with treatment responsiveness, which we successfully validate in mCRPC patient-derived xenograft (PDX) models. In silico analyses reveal histone deacetylase (HDAC)3 to critically drive resistance to hormonal interventions, which we validate in vitro. Critically, we identify the pan-HDAC inhibitor vorinostat to be effective in decreasing tumor cell proliferation, both in vitro and in vivo. Moreover, we uncover evidence for HDAC3 working together with Glucocorticoid Receptor (GR) as a potential mechanism for this therapeutic effect. These findings demonstrate the rationale for therapeutic strategies including HDAC inhibitors to improve patient outcome in advanced stages of mCRPC.

Keywords

H3K27ac; HDAC inhibitors; androgen receptor; biomarkers; drug resistance; enzalutamide; epigenetics; hormone intervention; mCRPC; prostate cancer.

Figures
Products